Esophagus verrucous carcinoma

Summary

Esophagus verrucous carcinoma (MONDO:0002762) is a cancer and 1 clinical trial. A subtype of esophageal squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	esophagus verrucous carcinoma
Mondo ID	MONDO:0002762
DOID	DOID:3747
NCIT	C27420
UMLS	C1333470
MedGen	272594
GARD	0023238
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	yes

Also known as: esophageal verrucous cancer · esophageal verrucous carcinoma · esophagus verrucous carcinoma · verrucous carcinoma of esophagus · verrucous carcinoma of the esophagus · verrucous carcinoma of the oesophagus

Disease family

This is a subtype of esophageal squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › esophageal squamous cell carcinoma › esophagus verrucous carcinoma

Related subtypes (3): esophageal adenosquamous carcinoma, esophageal basaloid carcinoma, undifferentiated carcinoma of esophagus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03584308	PHASE2	COMPLETED	Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal